Novavax Highlights Matrix-M Licensing Push, Oncology Ambitions at Cantor Conference

Novavax outlined a strategy to expand its Matrix-M adjuvant platform through licensing partnerships, internal research programs and commercialization alliances. The strategy signals potential avenues for broader platform monetization, but the provided article excerpt contains no financial targets, deal values, clinical data or earnings figures to quantify the impact.